Revium Rx (RVRC) Profit After Tax (2025 - 2026)
Revium Rx's (RVRC) quarterly Profit After Tax came in at -$748000.0 in Q2 2026, up 28.01% year-over-year from -$584339.8 in Q2 2025, and up 28.01% quarter-over-quarter from -$1.0 million in Q2 2025.
Powered by 
Analysis
Revium Rx (RVRC) Profit After Tax (2025 - 2026) Analysis & Trends
Revium Rx has disclosed Profit After Tax across 2 years of filings, most recently posting -$748000.0 for Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 472.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -782.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Revium Rx | 86.84 Mn | 85.34 Mn | - | -748,000.00 |